List of Excipients in Branded Drug SODIUM EDECRIN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aton Pharma Inc	SODIUM EDECRIN	ethacrynate sodium	25010-210	MANNITOL

Sodium Edecrin Excipient Strategy and Commercial Opportunities

Last updated: October 4, 2026

Sodium Edecrin is the injectable sodium salt of ethacrynic acid, a loop diuretic used when rapid diuresis is required or when a sulfonamide-derived loop diuretic may be unsuitable. Its active-ingredient patents and regulatory exclusivities are long expired. Commercial opportunity therefore depends on formulation execution, supply reliability, hospital economics, and differentiation from furosemide, bumetanide, and torsemide rather than on compound patent protection.

The most credible opportunity is a modern, ready-to-use or easy-to-reconstitute injectable product with controlled excipient burden, strong container-closure stability, and a hospital-focused presentation. A conventional tablet or undifferentiated lyophilized vial would face limited commercial upside.

What is Sodium Edecrin and how is it formulated?

Sodium Edecrin contains ethacrynate sodium, the sodium salt of ethacrynic acid. The product is associated with intravenous use when oral therapy is impractical or when an alternative to sulfonamide-containing loop diuretics is clinically preferred.

Current dosage forms and formulation characteristics

Attribute	Sodium Edecrin profile
Active ingredient	Ethacrynate sodium
Pharmacologic class	Loop diuretic
Primary use	Edema and acute fluid overload
Important clinical niche	Patients with potential sulfonamide hypersensitivity concerns
Injectable presentation	Sterile powder or vial-based injectable presentation
Oral presentation	Ethacrynic acid tablets are marketed separately from the sodium injectable salt
Key formulation issue	Aqueous stability, reconstitution, dilution, and container compatibility
Main competing drugs	Furosemide, bumetanide, torsemide
Regulatory pathway for a copy	505(j) ANDA if pharmaceutical equivalence and bioequivalence requirements can be met
Alternative pathway	505(b)(2) for a materially different formulation or delivery system

The injectable product uses excipients associated with powder reconstitution and solution administration. Public labeling identifies mannitol in the injectable formulation and permits pH adjustment with sodium hydroxide. The precise formulation, residual moisture specification, reconstitution time, solution stability, and container system are central development variables. [1]

What excipients are used in Sodium Edecrin injection?

The principal disclosed excipient strategy is conservative. The injectable product uses a bulking or stabilizing excipient, with pH adjustment to support product performance after reconstitution.

Mannitol

Mannitol can provide several functions in a sterile powder:

• Bulking material for vial fill.
• Cake structure in a lyophilized product.
• Osmolality contribution after reconstitution.
• Potential crystallization control in a dried formulation.

Mannitol is familiar to regulators and hospital pharmacists. It does not introduce the preservative, sulfite, or surfactant concerns associated with more complex injectable systems. Its use can support a low-excipient label, which is valuable for critically ill patients and hospital formulary review.

The main development risk is physical behavior during drying and storage. Mannitol can crystallize, produce variable cake structure, and affect reconstitution performance. A formulation using mannitol should control polymorphic form, residual moisture, vial headspace, and reconstitution time.

Sodium hydroxide and pH control

Sodium hydroxide is used for pH adjustment rather than as a principal functional excipient. It can support solubility and chemical stability, but excessive alkalinity can increase compatibility risks after dilution.

A new product should characterize:

• pH immediately after reconstitution.
• pH after dilution in common infusion fluids.
• Precipitation risk over the proposed administration period.
• Compatibility with polyvinyl chloride and polyolefin administration sets.
• Adsorption to infusion containers and tubing.
• Stability under refrigerated and room-temperature conditions.

Water for injection and diluents

A commercial opportunity exists in reducing the operational burden created by reconstitution. A manufacturer could develop:

1. A conventional sterile powder vial with a dedicated diluent.
2. A dual-chamber vial or transfer device.
3. A ready-to-use solution.
4. A pharmacy bulk package for controlled hospital preparation.
5. A premixed small-volume infusion bag.

The ready-to-use option has the clearest hospital value but also the highest technical burden because aqueous ethacrynate sodium stability must be demonstrated across the proposed shelf life and administration window.

What formulations are protected by Sodium Edecrin patents?

No meaningful current patent barrier is expected for the historical ethacrynic acid compound or the legacy Sodium Edecrin formulation. Ethacrynic acid was developed decades ago, and the core composition and therapeutic-use rights have expired.

Patent estate assessment

Patent category	Likely status	Commercial implication
Ethacrynic acid composition of matter	Expired	No compound exclusivity
Ethacrynate sodium injectable formulation	Legacy rights expired or unavailable as a blocking estate	Copy products can pursue conventional formulations
Basic loop-diuretic method of use	Expired or unenforceable as a commercial barrier	Limited method-of-use protection
Modern ready-to-use formulation	Potentially patentable if technically distinct	Main source of new exclusivity
Container-closure or device system	Potentially patentable	Can create narrower product protection
Manufacturing process	Potentially patentable as a process	May protect yield, impurity control, or stability improvements
Hospital admixture or compatibility method	Potentially patentable	Commercial value depends on practical adoption

A new entrant should not assume that the absence of compound patents eliminates all freedom-to-operate work. A current review should cover formulation patents, sterile manufacturing processes, drug-device combinations, packaging systems, and third-party excipient or premix technologies.

What is the FDA Orange Book status of Sodium Edecrin?

The relevant FDA regulatory question is whether a currently listed reference standard and approved product support an ANDA for the proposed dosage form and strength. The Orange Book, FDA labeling records, and the Approved Drug Products with Therapeutic Equivalence Evaluations database are the controlling sources for reference-product status and patent or exclusivity listings. [2]

Regulatory pathways

505(j) ANDA

An ANDA is the most economical pathway for a pharmaceutically equivalent injectable product if:

• The same active moiety and dosage form are used.
• The product matches the reference strength.
• The route of administration is the same.
• Pharmaceutical equivalence is established.
• Sterility, particulate matter, impurities, container closure, and stability meet FDA requirements.
• The applicant addresses listed patents and exclusivity.

For a legacy injectable, the principal barriers are often chemistry, manufacturing and controls requirements rather than patent litigation.

505(b)(2)

A 505(b)(2) application may be more suitable for:

• A ready-to-use solution where the reference is a powder.
• A novel concentration.
• A new infusion bag or delivery system.
• A new diluent or administration configuration.
• A formulation with a materially different stability profile.
• A clinically justified administration method.

This pathway can support differentiated labeling, but it may face additional clinical, pharmacokinetic, compatibility, and bridging requirements.

When does Sodium Edecrin lose exclusivity?

Sodium Edecrin has no commercially meaningful remaining new-drug exclusivity based on its historical approval date. The relevant market-access issue is product availability and reference-product status, not the expiration of a current exclusivity period.

No active exclusivity is expected to protect the historical product against standard generic development. Paragraph IV litigation is therefore less likely to center on the ethacrynic acid molecule. If litigation arises, it would more likely involve a later entrant’s formulation, device, manufacturing process, or use patent.

Are there Paragraph IV challenges to Sodium Edecrin?

A conventional Paragraph IV challenge would have limited strategic value if the reference product has no blocking patents listed in the Orange Book. Paragraph IV certification becomes commercially relevant only when an applicant seeks approval against a listed patent or when a patent holder asserts a later-filed formulation or method-of-use patent.

The practical generic strategy is more likely to involve:

• Paragraph III certification if a valid listed patent remains.
• Paragraph IV certification if a listed patent is considered invalid or not infringed.
• A section viii statement for non-patented indications.
• A 505(b)(2) application that avoids direct reliance on a particular listed formulation.

The low probability of core patent litigation increases the importance of early FDA product-specific guidance and formulation reproducibility.

What excipient strategy creates the strongest commercial opportunity?

The strongest strategy combines a minimal-excipient formulation with a lower-burden hospital presentation.

Option 1: Ready-to-use injectable solution

A ready-to-use solution could eliminate vial reconstitution, reduce compounding steps, and lower medication-preparation risk. The commercial advantages include:

• Shorter administration preparation time.
• Lower risk of reconstitution error.
• Easier use in emergency departments and intensive-care units.
• Potential reduction in pharmacy handling.
• Simplified bar-code and automated dispensing workflows.

The technical challenge is maintaining chemical stability without excessive pH adjustment, preservatives, surfactants, or complex packaging.

Option 2: Improved lyophilized vial

An improved sterile powder may be the most realistic 505(j)-adjacent opportunity. Differentiation could come from:

• Faster reconstitution.
• Lower vial overfill.
• More consistent cake structure.
• Improved stability under temperature excursions.
• A smaller vial or more efficient packaging.
• A supplied diluent and transfer system.

This approach has lower development risk than a ready-to-use solution but may have weaker pricing power.

Option 3: Premixed infusion bag

A premixed bag would target institutional use and could compete on workflow rather than pharmacology. Relevant design parameters include:

• Infusion volume.
• Final concentration.
• Administration time.
• Bag material.
• Light protection.
• Shelf life.
• Compatibility with standard infusion pumps.

The bag format may create meaningful differentiation if the product remains stable without precipitation, adsorption, or impurity growth. It also creates additional manufacturing and logistics requirements.

Option 4: Preservative-free, low-sulfite injectable

Ethacrynic acid is clinically relevant partly because it is not a sulfonamide derivative. A product positioned around low excipient burden and the absence of unnecessary preservatives could reinforce that distinction.

A preservative-free presentation is especially relevant for intravenous products used in acutely ill patients. The commercial claim must remain tied to objective formulation attributes and approved labeling.

How does Sodium Edecrin compare with competing loop diuretics?

Product	Active ingredient	Primary commercial strength	Key limitation
Sodium Edecrin	Ethacrynate sodium	Alternative for patients where sulfonamide concerns affect drug selection; IV niche	Small market, ototoxicity concern, limited routine use
Lasix and generics	Furosemide	Broad availability, low cost, extensive clinical familiarity	Sulfonamide structure; variable absorption orally
Bumex and generics	Bumetanide	Potent loop diuretic with IV and oral use	Higher unit cost than furosemide
Demadex and generics	Torsemide	Oral use and longer duration in selected settings	Less central role in urgent IV diuresis

Sodium Edecrin is unlikely to win broad volume share from furosemide. Its opportunity is in targeted segments where clinicians value a non-sulfonamide loop-diuretic option, rapid parenteral administration, or supply diversification.

What generic entry risks exist?

Generic entry risk is high for a conventional Sodium Edecrin copy because the active ingredient is old, the dosage form is established, and the patent barrier is limited. The main risks are commercial:

• Small total addressable market.
• Low purchasing prices for hospital generics.
• Limited formulary demand.
• Existing clinical substitution by furosemide.
• Manufacturing complexity for sterile injectable products.
• Potential shortage exposure if only a few suppliers remain.
• Ototoxicity concerns that constrain routine use.

A differentiated product can reduce direct price competition, but the market may not support premium pricing unless the product solves a measurable hospital problem.

Which companies are challenging or competing with Sodium Edecrin?

The competitive landscape is broader than direct ethacrynate sodium products. Generic manufacturers of furosemide, bumetanide, and torsemide compete for the same edema and fluid-overload treatment budgets. Hospital purchasing groups also evaluate supply continuity, contract price, shortage history, and operational simplicity.

Direct competition may come from:

• Generic injectable ethacrynate sodium suppliers.
• Specialty injectable manufacturers.
• Hospital-focused generic companies.
• 505(b)(2) developers of ready-to-use diuretic presentations.
• Contract manufacturers with sterile lyophilization capacity.

The most defensible competitive position would combine reliable supply with a formulation that lowers pharmacy preparation time.

What manufacturing and intellectual-property barriers matter?

The active ingredient is not the main barrier. The higher-value manufacturing capabilities are:

• Sterile powder filling or aseptic solution filling.
• Control of ethacrynic acid-related impurities.
• Reproducible pH adjustment.
• Lyophilization-cycle development.
• Moisture and oxygen control.
• Container-closure integrity.
• Stability-indicating analytical methods.
• Compatibility testing with infusion materials.
• Scale-up without altered reconstitution performance.

A patentable manufacturing process could cover impurity reduction, enhanced stability, a defined solid-state form, or a controlled drying cycle. Such rights would be narrower than a compound patent and would require strong evidence that the process produces a commercially meaningful product attribute.

What licensing deals could support a Sodium Edecrin product?

Licensing value would likely arise from manufacturing assets rather than from the active ingredient. Potential deal structures include:

• In-licensing a ready-to-use injectable platform.
• Contract manufacturing with a sterile injectable specialist.
• Acquisition of an established ethacrynate sodium ANDA.
• Licensing a dual-chamber vial or transfer device.
• Co-development with a hospital-generic company.
• Supply and distribution agreements with institutional wholesalers.

A license should prioritize rights to the formulation, container system, regulatory dossier, and manufacturing process. Rights limited to ethacrynic acid itself would have little strategic value.

What is the revenue exposure and commercial ceiling?

Sodium Edecrin is a niche hospital product. Revenue potential is constrained by clinical substitution and low utilization compared with furosemide. A product can still command strategic value if it captures:

• Sulfonamide-allergy or sulfonamide-avoidance cases.
• Acute-care and intensive-care demand.
• Shortage-driven substitution.
• Hospitals seeking a second-source injectable.
• Pediatric or specialized institutional use where formulation simplicity has value.

The commercial model should assume low-to-moderate unit volume and evaluate profitability through price, gross margin, manufacturing utilization, and supply contracts. A small product with reliable shortage performance may have more value than a high-volume product exposed to aggressive generic price erosion.

Key Takeaways

• Sodium Edecrin is an old ethacrynic acid product with no meaningful remaining compound exclusivity.
• The most attractive opportunity is a differentiated injectable presentation, not a conventional copy.
• Mannitol and pH adjustment represent a simple, regulator-familiar excipient platform.
• Ready-to-use solutions and premixed infusion bags offer the strongest workflow differentiation.
• A 505(j) ANDA is likely to be the lowest-cost route for a conventional equivalent product.
• A 505(b)(2) pathway may support novel concentrations, ready-to-use products, or device-enabled presentations.
• Core patent litigation and Paragraph IV risk are likely to be limited unless a new formulation or process patent is asserted.
• Commercial success depends on hospital workflow, supply reliability, and niche clinical demand.
• The principal technical risks are aqueous stability, reconstitution performance, container compatibility, and sterile manufacturing scale-up.

FAQs About Sodium Edecrin Excipient Strategy

Is Sodium Edecrin a sulfonamide loop diuretic?

No. Sodium Edecrin is the sodium salt of ethacrynic acid and is structurally distinct from sulfonamide-derived loop diuretics such as furosemide, bumetanide, and torsemide.

Can mannitol be replaced in a Sodium Edecrin injectable?

Potentially. Alternatives would need to preserve cake structure, reconstitution performance, stability, osmolality, and injectable safety. Any replacement would require a full formulation and regulatory comparability assessment.

Would a ready-to-use Sodium Edecrin product qualify for an ANDA?

It may not qualify as a straightforward ANDA if the reference product is a reconstituted powder and the new product has materially different composition, concentration, or presentation. A 505(b)(2) pathway may be appropriate for a substantially different formulation.

What patent claims could protect a new Sodium Edecrin formulation?

Potential claims could cover a stable aqueous composition, a defined impurity profile, a solid-state form, a lyophilized cake, a premixed infusion bag, a dual-chamber container, or a manufacturing process that improves stability or reconstitution.

Why is Sodium Edecrin commercially relevant despite its small market?

It addresses a specialized clinical need and can provide an alternative when sulfonamide-derived loop diuretics are unsuitable. A reliable, easy-to-use injectable product may also obtain institutional value through shortage mitigation and pharmacy workflow savings.

References

1. U.S. Food and Drug Administration. (n.d.). Edecrin (ethacrynic acid) prescribing information. FDA/DailyMed labeling records.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. U.S. Food and Drug Administration. (2022). ANDA submissions: Content and format of an abbreviated new drug application. FDA guidance and regulatory materials.
4. U.S. Food and Drug Administration. (2023). Reference listed drugs and reference standards: Regulatory information for generic drug development. FDA regulatory resources.